Defective peroxisomal proliferators activated receptor gamma activity due to dominant-negative mutation synergizes with hypertension to accelerate cardiac fibrosis in mice

Kis, Adrienn, Murdoch, Colin, Zhang, Min, Siva, Anjana, Rodriguez-Cuenca, Sergio, Carobbio, Stefania, Lukasik, Agnes, Blount, Margaret, O'Rahilly, Steve, Gray, Sarah L., Shah, Ajay M. and Vidal-Puig, Antonio (2009). Defective peroxisomal proliferators activated receptor gamma activity due to dominant-negative mutation synergizes with hypertension to accelerate cardiac fibrosis in mice. European Journal of Heart Failure, 11 (6), pp. 533-541.

Abstract

Aims Humans with inactivating mutations in peroxisomal proliferators activated receptor gamma (PPARγ) typically develop a complex metabolic syndrome characterized by insulin resistance, diabetes, lipodystrophy, hypertension, and dyslipidaemia which is likely to increase their cardiovascular risk. Despite evidence that the activation of PPARγ may prevent cardiac fibrosis and hypertrophy, recent evidence has suggested that pharmacological activation of PPARγ causes increased cardiovascular mortality. In this study, we investigated the effects of defective PPARγ function on the development of cardiac fibrosis and hypertrophy in a murine model carrying a human dominant‐negative mutation in PPARγ. Methods and results Mice with a dominant‐negative point mutation in PPARγ (P465L) and their wild‐type (WT) littermates were treated with either subcutaneous angiotensin II (AngII) infusion or saline for 2 weeks. Heterozygous P465L and WT mice developed a similar increase in systolic blood pressure, but the mutant mice developed significantly more severe cardiac fibrosis to AngII that correlated with increased expression of profibrotic genes. Both groups similarly increased the heart weight to body weight ratio compared with saline‐treated controls. There were no differences in fibrosis between saline‐treated WT and P465L mice. Conclusion These results show synergistic pathogenic effects between the presence of defective PPARγ and AngII‐induced hypertension and suggest that patients with PPARγ mutation and hypertension may need more aggressive therapeutic measures to reduce the risk of accelerated cardiac fibrosis.

Publication DOI: https://doi.org/10.1093/eurjhf/hfp048
Divisions: Life & Health Sciences > Biosciences
Aston Medical School
Additional Information: Published on behalf of the European Society of Cardiology. All rights reserved. © 2009 the Authors This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Uncontrolled Keywords: hypertension,left ventricular hypertrophy,interstitial fibrosis,dominant-negative PPARγ,lipodystrophy
Full Text Link: http://onlinelibrary.wiley.com/doi/10.1093/eurjhf/hfp048/abstract
Related URLs: http://www.scopus.com/inward/record.url?scp=68949144596&partnerID=8YFLogxK (Scopus URL)
Published Date: 2009-06
Authors: Kis, Adrienn
Murdoch, Colin ( 0000-0002-0274-819X)
Zhang, Min
Siva, Anjana
Rodriguez-Cuenca, Sergio
Carobbio, Stefania
Lukasik, Agnes
Blount, Margaret
O'Rahilly, Steve
Gray, Sarah L.
Shah, Ajay M.
Vidal-Puig, Antonio

Download

Export / Share Citation


Statistics

Additional statistics for this record